Kite Pharma Says Death Of Patient Not Related To Cancer Treatment Trial

Kite Pharma admitted that there was indeed a patient who died during the early stage trial of its CAR-T drug KTE-C19 therapy, but the incident was found to be unrelated to experimental treatment for non-Hodgkin's lymphoma.